A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Completed · Phase 2 · NCT04699630
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
At a glance
- Research payments reported, 2025
- $506,346
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 121
About the trial
- Sponsor
- SCRI Development Innovations, LLC (with Daiichi Sankyo)
- Tested
- U3-1402 (drug)
- Dates
- Started 2021-05-03; completion 2025-04-09
- Results posted
- Yes
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $506,346 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Yuan Yuan, M.D., PH.D. Medical Oncology · Pasadena, CA
- Nusayba A. Bagegni, MD Medical Oncology · Saint Louis, MO
- Arielle L. Heeke, MD Hematology · Charlotte, NC
- Nancy Chan, MD Medical Oncology · New York, NY
- William R. Gwin III, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Washington Medical Ctr, WA $188,749
- City of Hope National Medical Ctr $137,608
- Washington University $109,677
- Carolinas Medical Center-Northeast, NC $34,182
- Rutgers the State University of New Jersey $26,680
- Highlands Oncology Group $9,450
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.